Lucatumumab

DB06360Investigational

Investigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified).

Mechanism: HCD122 is a fully human, antagonist antibody that targets the CD40 antigen. HCD122 binds to tumor cells that express CD40 and antagonizes (prevents) CD40 ligand-mediated growth and survival of malignant B cells. Based on preclinical data, HCD122 also induces antibody-dependent cellular cytotoxicity (ADCC), killing CD40 expressing tumor cells by immune effector cells. This dual mechanism of action makes HCD122 a drug candidate with potential for the treatment of B-cell malignancies.
Curator reviewed
Primary indication: Investigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified).Curator reviewed
Code names: CHIR-12.12 · HCD-122

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

382Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lucatumumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.